C4 Therapeutics, Inc. (CCCC) — 10-Q Filings

10-Q Filings (6)

• C4 Therapeutics' Losses Widen Amid Revenue Dip, Asset Impairment — Nov 6, 2025 Risk: high
  C4 Therapeutics, Inc. (CCCC) reported a net loss of $32.166 million for the three months ended September 30, 2025, an increase from a net loss of $24.666 millio
• C4 Therapeutics' Q2 Net Loss Widens to $48.2M Amid R&D Push — Aug 7, 2025 Risk: high
  C4 Therapeutics, Inc. reported a net loss of $48.2 million for the three months ended June 30, 2025, a significant increase from the $38.5 million net loss in t
• C4 Therapeutics Files Q1 2025 10-Q — May 7, 2025 Risk: medium
  C4 Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, based in Watertown, MA, is involved in biological products. Key financia
• C4 Therapeutics Files Q3 2024 10-Q — Oct 31, 2024 Risk: medium
  C4 Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business o
• C4 Therapeutics Files Q2 2024 10-Q — Aug 1, 2024 Risk: medium
  C4 Therapeutics, Inc. filed a 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations.
• C4 Therapeutics Files Q1 2024 Report — May 8, 2024 Risk: low
  C4 Therapeutics, Inc. filed its quarterly report for the period ended March 31, 2024. The company is incorporated in Delaware and its principal executive office

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX